NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOVIST II (diatrizoate meglumine) is an injectable contrast agent used for diagnostic imaging procedures to visualize internal body structures. It is a small-molecule radiographic contrast medium administered via injection for enhanced visualization during medical imaging studies. The drug functions by increasing radiographic density in targeted tissues, enabling clearer diagnostic visualization.
LOE Approaching
As a mature, off-patent contrast agent facing LOE, the brand team is likely focused on maintaining market share against generics and newer formulations with minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENOVIST II offers limited career growth upside given its LOE-approaching lifecycle and minimal linked job openings. Roles are primarily focused on sustaining market share, managing generic competition, and operational efficiency rather than innovation or expansion.
Field SalesBrand Manager
Worked on RENOVIST II at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.